CFP and hepatocellular carcinoma: CFP is significantly downregulated in HCC, and its low expression is associated with poorer overall survival (OS) and disease-free survival (DFS), suggesting that it may serve as a potential prognostic biomarker and immune-related therapeutic target [64].